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Chlamydial Positivity of Nasal Discharge at Baseline Is
Associated with Ocular Chlamydial Positivity 2 Months
following Azithromycin Treatment
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BACKGROUND. Trachoma is the leading infectious cause of blind-
ness. Routes of transmission remain unclear. In this study, the
relationship between Chlamydia trachomatis Amplicor-posi-
tive nasal discharge and Amplicor-positive ocular swabs was
investigated (Amplicor; Roche, Indianapolis, IN).
METHODS. A longitudinal study was conducted in Tanzania and
The Gambia. Eyes were graded for active trachoma; ocular
swabs were taken to test for C. trachomatis. Children with
visible nasal discharge had swabs taken of this material. Partic-
ipants were offered systemic antibiotics. Two months after
treatment, participants were re-examined.
RESULTS. Of the 1128 children participating, 188 (17%) had
nasal discharge. Among 188 children with nasal discharge, 64
(34%) nasal swabs were PCR positive. There was a strong
correlation between active disease/ocular chlamydial positivity
and positive nasal discharge. Children with Amplicor-positive
ocular swabs were 9.9 times more likely to have Amplicor-
positive nasal discharge than were children without ocular
positivity (95% CI: 4.34–22.53). Two months after treatment,
16% had an Amplicor-positive ocular swab. Children with pos-
itive nasal discharge at baseline were 5.2 times more likely to
have an Amplicor-positive ocular swab at 2 months than were
children without Amplicor-positive nasal discharge at baseline
(95% CI: 1.54–17.23), after adjusting for baseline ocular posi-
tivity, gender, and study site.
CONCLUSIONS. Nasal discharge may provide a source of reinfec-
tion with C. trachomatis, after antibiotic treatment for tra-
choma, either through transfer of secretions from nose to eye
or from nasal secretions transferred to bed sheets or dirty
clothes and back to the eye; alternatively, nasal discharge may
be an indicator of severe persistent ocular chlamydial infection
that is not cleared with a single dose of antibiotics. (Invest
Ophthalmol Vis Sci. 2006;47:4767–4771) DOI:10.1167/
iovs.05-1599
Trachoma, a disease caused by ocular infection with Chla-mydia trachomatis, remains hyperendemic in many parts
of the world and is the leading infectious cause of blindness
worldwide.1 Although trachoma manifests itself through ocular
signs and symptoms, C. trachomatis can infect other epithelial
surfaces, notably the nasopharynx and gastrointestinal tract.2
Risk factors for active trachoma have been characterized,3–8
but routes of transmission are not fully understood.
The World Health Organization has endorsed a strategy
known as “SAFE” to help reduce the burden of blinding tra-
choma worldwide. The components of the SAFE strategy in-
clude Surgery to correct inturned lashes, Antibiotics to treat
active trachoma, Face-washing to improve hygiene, and Envi-
ronmental improvements. When face-washing is evaluated
within a community, the primary marker for a “dirty” face is
the presence of ocular and/or nasal discharge, because this
discharge attracts flies, and may be infected. The F component
of the SAFE strategy was included based on the results of
studies that have shown an association between good personal
hygiene (including maintaining a clean face) and lower risk of
trachoma.5,7–10 In a clinical trial of face-washing in Tanzania,
West et al.8 demonstrated that having a clean face at two or
more follow-up visits was protective against both any trachoma
(OR: 0.58; 95% CI: 0.47–0.72) and severe trachoma (OR: 0.35;
95% CI: 0.21–0.59). In that trial, 25% of children had clean
faces at baseline, defined as having no nasal discharge, ocular
discharge, or flies on the face. Previous studies have reported
the presence of C. trachomatis from both nasal and rectal
swabs.2,11 These data suggest that nasal discharge may play a
role in trachoma transmission and may result in reinfection.
Data from longitudinal studies conducted in The Gambia
and Tanzania provide the opportunity to assess the relationship
between positive nasal discharge at baseline and Amplicor-
positive ocular swabs 2 months after systemic treatment (Am-
plicor; Roche, Indianapolis, IN).
METHODS
This study was performed in three sites, two in Tanzania and one in
The Gambia, each with different levels of trachoma endemicity. In
Tanzania, the study was conducted in the subvillage of Maindi, in the
Dodoma District of central Tanzania and in the Kahe Mpya subvillage
in the Rombo District of northern Tanzania. In The Gambia, the study
was conducted in a cluster of 14 small villages in Jareng, Upper Saloum
District. Details of the main studies are described elsewhere.12–16
Briefly, a census was taken of each site, and a survey was conducted of
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all consenting residents. Each consenting resident underwent an ocu-
lar examination to evaluate active trachoma and had a conjunctival
swab taken.
In Tanzania, trachoma was graded according to the World Health
Organization (WHO) simplified grading scheme,17 whereas in The
Gambia the modified WHO grading scheme (FPC system [follicles,
papillae, cicatrices]) was used.18 For this report, the FPC system was
converted to the WHO-modified grading scheme to provide consis-
tency in grading across sites. Ocular swabs were taken of the tarsal
conjunctiva of the right eye (Maindi and Rombo) or left eye (Jareng) of
each participant. Children aged less than 9 years with nasal discharge
visible outside the margin of the nostril had an additional swab taken
of this material. Standard precautions were taken against cross-contam-
ination of samples for different subjects. These precautions were
similar across sites, with some slight variations by site. In Rombo, the
examiner wore two pairs of latex gloves while examining each subject.
Between subjects, he removed the outer pair, sprayed the exterior of
the inner pair with alcohol and allowed them to dry before donning
another pair. Only the examiner touched the swab, which was
snapped off into the collection tube without the use of scissors or a
blade. In The Gambia and Kongwa, two individuals worked together to
collect the ocular swabs. The examiner everted the lid, while the
specimen collector rubbed the Dacron tip across the conjunctiva. The
specimen collector snapped off the swab into the tube so that the part
that the specimen collector had touched did not enter the tube. Hands
were washed between participants. Swabs were stored dry on ice in
the field and frozen at 20° within 8 hours of collection, until they
were transported to the London School of Hygiene and Tropical Med-
icine for processing. After examination, all individuals in the village
were offered a single dose of oral azithromycin, 20 mg/kg up to a
maximum of 1 g.
Ocular and nasal swabs were processed by procedures identical
with those described previously.16 Briefly, once received, laboratory
technicians extracted the DNA from the swabs by adding molecular-
grade water and vortexing them. A second detergent was then added
to finish the preparation of the specimens for analysis. Standard DNA
amplification techniques using the Amplicor Chlamydia trachomatis
qualitative PCR assay were used to analyze the specimens according to
the colorimetric assay in the package insert (Roche Molecular Systems,
Branchburg, NJ). Equivocal specimens were reassayed and assigned a
positive value if optical density results were still between 0.2 and 0.8.
Because we cannot be certain whether the detection of C. trachomatis
DNA in swabs of nasal discharge reflects true C. trachomatis infection
of the nasopharynx or simply drainage of ocular secretions from an
infected conjunctival epithelium via the nasolacrimal duct, we have
chosen to refer to a sample of nasal discharge that tested positive for
C. trachomatis as an “Amplicor-positive nasal discharge” throughout
the text. Likewise, low loads of ocular chlamydia do not necessarily
translate to biological activity; therefore, we have chosen to be con-
servative in our description of ocular positivity, referring to swabs as
“Amplicor-positive ocular swabs.”
Although all individuals living in the study villages were invited to
participate in the study and were offered antibiotic treatment, for the
purposes of this report, evaluation was limited to children aged 9
years, as these individuals are the ones from whom swabs of nasal
discharge were taken. Frequency tables and Mantel-Haenszel tests for
trend were used to evaluate bivariate associations. Logistic regression
was used to evaluate the association between ocular positivity and
Amplicor-positive nasal discharge at baseline, after adjusting for gender
and study site. Multivariate logistic regression also was used to evaluate
the association between Amplicor-positive nasal discharge at baseline
and ocular positivity 2 months after treatment, after controlling for
baseline positivity, gender, and study site. All study procedures were
approved by the Johns Hopkins Joint Committee on Clinical Investiga-
tion, the London School of Hygiene and Tropical Medicine and the
in-country Institutional Review Boards. The study complied with the
tenets of the Declaration of Helsinki.
RESULTS
We examined 1128 children aged 9 years from three villages
(Table 1). In this age group, clinically active trachoma preva-
lence at baseline was highest in Maindi (75.6%) and lowest in
Jareng (15.8%). Among all children examined, 188 (16.7%) had
fresh, wet nasal discharge at baseline, and a swab was taken of
this material. Children with active trachoma were 3.2 times
more likely to have nasal discharge than were children without
clinical signs of trachoma (95% CI: 2.29–4.39). Children with
nasal swabs taken were, on average, younger than those with-
out nasal swabs taken. A total of 64 (34%) nasal swabs were
PCR positive. Compared with the village population aged 9
years without nasal discharge, children with nasal discharge
were more likely to have active disease (follicular trachoma
[TF] and/or trachoma inflammation [TI]) than children with no
nasal discharge (P  0.0001).
TABLE 1. Characteristics of Participants Aged 9 Years with and without Nasal Swabs Taken

























Participants 225 74 271 58 444 56 940 188
Female 120 (53.3) 44 (59.5) 124 (45.8) 30 (51.7) 217 (48.9) 28 (50.0) 461 (49.0) 102 (54.3)
Age (y)
0.5 to 2 43 (19.1) 11 (14.9) 63 (23.2) 8 (13.8) 106 (23.9) 8 (14.3) 212 (22.6) 27 (13.8)
2 to 3 52 (23.1) 28 (37.8) 57 (21.0) 16 (27.6) 78 (17.6) 25 (44.6) 187 (19.9) 69 (36.7)
4 to 5 41 (18.2) 21 (28.4) 59 (21.8) 20 (34.5) 106 (23.9) 15 (26.8) 206 (21.9) 56 (29.8)
6 to 8 89 (39.6) 14 (18.9) 92 (34.0) 14 (24.1) 154 (34.7) 8 (14.3) 335 (35.6) 36 (19.5)
Trachoma status
No active
disease 61 (27.1) 12 (16.2) 163 (60.2) 21 (36.2) 385 (86.7) 36 (64.3) 609 (64.8) 69 (36.7)
TF 113 (50.2) 46 (62.2) 44 (16.2) 17 (24.1) 51 (11.5) 16 (28.6) 208 (22.1) 76 (40.4)
TI / TF 51 (22.7) 16 (21.6) 64 (23.6) 23 (39.7) 8 (1.8) 4 (7.1) 123 (13.1) 43 (22.9)
Swab positivity
Ocular 152 (67.9)* 50 (67.6) 38 (14.0) 14 (24.1) 34 (7.8)* 9 (16.1) 224 (24.0) 73 (38.8)
Nasal — 44 (59.5) — 16 (27.6) — 4 (7.1) — 64 (34.0)
Data are the number (percentage of the total group).
* One individual from Maindi and seven from Jareng did not have ocular infection information.
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Active Disease and Nasal Discharge
Among children with nasal swabs taken, a strong association
between active disease (TF and/or TI) and positive nasal dis-
charge was noted across all study sites (Table 2). Furthermore,
children with intense trachoma inflammation (TI) were more
likely to have Amplicor-positive nasal discharge than were
individuals with follicular trachoma (TF; P  0.035). For each
study site, 50% to 88% of children with nasal discharge and TI
had Amplicor-positive nasal discharge, whereas very few chil-
dren without TF or TI had Amplicor-positive nasal discharge.
Among children without signs of active trachoma, the preva-
lence of Amplicor-positive nasal discharge ranged from 4% to
18% across study sites. The association between active disease
and Amplicor-positive nasal discharge was strongest in Maindi,
where the highest level of endemicity also was reported.
Ocular Positivity and Nasal Positivity
A similar association was observed between ocular positivity
and Amplicor-positive nasal discharge (Table 2). Overall, nearly
60% (13/22) of children with Amplicor-positive ocular swabs
also had Amplicor-positive nasal discharge, whereas only 12%
(14/115) of children with a negative ocular swab had Amplicor-
positive nasal discharge. Again, the association was strongest in
Maindi, where trachoma prevalence was highest.
Age and Nasal Positivity
Across all ages studied, there was an association between
active disease and Amplicor-positive nasal discharge. The
strength of the association between TI and Amplicor-positive
nasal discharge increased with age. For children aged 2,
42.9% with TI had Amplicor-positive nasal discharge, whereas
87.5% of children aged 6 to 8 years with TI also had Amplicor-
positive nasal discharge. In a logistic regression model predict-
ing Amplicor-positive nasal discharge that included age, TI and
the interaction of age and TI, the interaction term was border-
line significant (P  0.13). After adjustment for gender and
village, the association between ocular positivity and Amplicor-
positive nasal discharge at baseline remained. Children with an
Amplicor-positive ocular swab were 9.9 times more likely to
have Amplicor-positive nasal discharge than were children
with negative ocular swabs (95% CI: 4.34–22.53).
Treatment coverage for this population was high. In Maindi,
86% of the total population and 97% of children aged 9 were
treated. Similarly, in Rombo, 98% of the entire population and
100% of children aged 9 were treated, and in Jareng, 83% of
the entire population and 89% of children aged 9 were
treated. Three children from Maindi who had nasal swabs
taken at baseline were not treated; in Rombo and Jareng, all
children with nasal swabs taken were treated.
Positivity at 2 Months after Treatment
Of the 188 children with nasal discharge at baseline, 169 were
examined 2 months after treatment, and 27 (16%) of these
children had an Amplicor-positive ocular swab at 2 months
(Table 3). In comparison, among the 833 children who did not
have a nasal swab taken at baseline but did have an ocular swab
TABLE 2. Individuals with Amplicor-Positive Nasal Discharge at Baseline according to Clinical Trachoma
Status and Ocular C. trachomatis Positivity
Maindi Rombo Jareng Overall*
Trachoma status
Neither TF nor TI 2/12 (16.7) 1/21 (4.8) 0/36 (0.0) 3/69 (4.4)
TF 28/46 (60.9) 3/14 (21.4) 2/16 (12.5) 33/76 (43.4)
TI / TF 14/16 (87.5) 12/23 (52.2) 2/4 (50.0) 28/43 (65.1)
Total 44/74 (59.5) 16/58 (27.6) 4/56 (7.1) 64/188 (34.0)
Ocular swab positivity
No 8/24 (33.3) 6/44 (13.6) 0/47 (0.0) 14/115 (12.2)
Yes 36/50 (72.0) 10/14 (71.4) 4/9 (44.4) 13/22 (59.1)
Total 42/74 (59.5) 16/58 (27.6) 4/56 (7.1) 64/188 (34.0)
Data are the number (percentage of the total group).
* P  0.0001 Mantel-Haenszel test for trend, overall for clinical trachoma status, and ocular swab
positivity.
TABLE 3. Characteristics of Ocular Positivity at 2 Months among Treated Participants
Characteristic Maindi* Rombo Jareng All Sites P†
Total participants 14/61 (23.0) 7/55 (12.8) 6/53 (11.3) 27/169 (16.0)
Age (y)
0.5 to 2 1/10 (10.0) 0/6 (0.0) 1/8 (12.5) 2/24 (8.3)
2 to 3 5/23 (21.7) 4/16 (25.0) 3/24 (12.5) 12/63 (19.0) 0.56
4 to 5 5/17 (29.4) 2/19 (10.5) 2/13 (15.4) 9/49 (18.3)
6 to 8 3/10 (30.0) 1/14 (7.1) 0/8 (0) 4/33 (12.1)
Baseline nasal swab positivity
No 2/24 (8.3) 1/39 (2.6) 4/49 (8.1) 7/112 (6.3)
Yes 12/36 (33.3) 6/16 (37.5) 2/4 (50.0) 20/56 (35.7) 0.0001
Baseline ocular swab positivity
No 3/19 (15.8) 1/41 (2.4) 1/44 (2.2) 5/104 (4.8)
Yes 11/41 (26.8) 6/14 (42.9) 5/9 (55.6) 22/64 (34.4) 0.0001
Data are the number of subjects with positive ocular swabs at 2 months/total number of subjects (%).
* One participant did not have an ocular swab taken at 2 months, but was examined at 2 months. Both
nasal and ocular swabs at baseline were negative.
† 2 P.
IOVS, November 2006, Vol. 47, No. 11 Chlamydial Positivity Associated with Positive Nasal Discharge 4769
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932936/ on 12/12/2017
taken at follow-up, 64 (7.7%) had an Amplicor-positive ocular
swab at 2 months (P  0.001). Of note, we found an associa-
tion between Amplicor-positive nasal discharge at baseline and
ocular positivity at 2 months, even after controlling for baseline
ocular positivity. Children with Amplicor-positive nasal dis-
charge at baseline were 5.2 times more likely to have an
Amplicor-positive ocular swab at 2 months than were children
without Amplicor-positive nasal discharge at baseline after ad-
justment for gender, study site, and baseline ocular positivity
(Table 4).
Fourteen children had Amplicor-positive nasal discharge at
baseline but had a PCR-negative ocular swab. Of note, 28%
(1/14) of these children had an Amplicor-positive ocular swab
at 2 months, whereas only 1 of 90 children without Amplicor-
positive nasal discharge and no ocular positivity at baseline had
an Amplicor-positive ocular swab at 2 months (Table 5). This
rate of positivity was similar to the 2-month positivity rate of
children with ocular positivity but without Amplicor-positive
nasal discharge at baseline. Children with both Amplicor-pos-
itive nasal discharge and ocular positivity at baseline were most
likely to have an Amplicor-positive ocular swab at 2 months.
DISCUSSION
C. trachomatis in nasal discharge was common in young chil-
dren in trachoma-endemic areas, and Amplicor-positive nasal
discharge at baseline was associated with ocular positivity at 2
months, independently of baseline ocular positivity. Although
the finding of C. trachomatis–positive nasal discharge has been
reported from Kongwa,11 this study confirms it in another area
of Tanzania and The Gambia. As expected, there was a strong
association between trachoma, or ocular chlamydial positivity
and Amplicor-positive nasal discharge. West et al.7 previously
demonstrated that in trachoma-endemic areas, approximately
10% of children have constant, severe trachoma, and these
children are more likely to advance to scarring. Our data
suggest that perhaps these children also are more likely to have
more extraocular infection, indicating a failure to clear infec-
tion from all sites. Longitudinal data to determine the risk of
ongoing, severe trachoma in this subgroup would confirm this
supposition.
A small group of children had an Amplicor-positive ocular
swab at 2 months after treatment with azithromycin. We have
previously shown in Maindi that such children are more likely
to be very young and to have ocular infection at baseline.13 The
present study shows that posttreatment ocular positivity also is
related to Amplicor-positive nasal discharge, independent of
ocular positivity at baseline. This association may be due to a
variety of factors. First, nasal discharge is frequently wiped
from the face with a handkerchief or other cloth that also is
used to wipe the eyes. If nasal discharge is infected with C.
trachomatis, it is possible that continual ocular reinfection
may occur as a result of self-reinoculation. These children also
typically sleep in close quarters on bedclothes or goatskins that
are rarely cleaned. Amplicor-positive nasal discharge may then
be a source of reinfection created by the individuals them-
selves or one of their close contacts, such as children sharing
the same sleeping space.
Alternatively, the association between Amplicor-positive na-
sal discharge and ocular positivity after treatment may be
explained by heavier extraocular infections among these indi-
viduals that are not cleared by the antibiotic regimen (a single
dose of 20 mg azithromycin/kg body weight, as recommended
by the WHO) used against trachoma in these studies. A study to
evaluate the relative effect of higher or multiple doses of
azithromycin would be necessary to evaluate this possibility. A
further possibility is that this association is due to azithromy-
cin-resistant C. trachomatis strains; however, to date no data
have demonstrated the emergence of antimicrobial resistance
in ocular isolates of this organism.
We recognize that we were testing nasal discharge, which is
unlikely to contain epithelial cells; therefore, the positivity that
we have noted must come from elementary bodies, not intra-
cellular infection. From our data, we cannot determine
whether indeed Amplicor-positive nasal discharge is a true
nasopharyngeal infection or whether positivity resulted from
drainage of ocular secretions through the nasolacrimal ducts.
However, the association between Amplicor-positive nasal dis-
charge at baseline and ocular positivity at 2 months suggests
that this discharge may be an important source of transmission
or reinfection. As noted by our finding among children without
ocular positivity at baseline, children with Amplicor-positive
nasal discharge were more likely to have ocular positivity at 2
months.
In summary, we have shown that nasal discharge of chil-
dren with active trachoma is frequently positive for C. tracho-
matis and that children with an Amplicor-positive nasal dis-
charge are more likely to have an Amplicor-positive ocular
swab after treatment than are children with nasal discharge
that is C. trachomatis–negative or children without nasal dis-
charge. These data suggest that nasal discharge may be a
source of trachoma transmission within trachoma-endemic ar-
eas through transfer of nasal secretions directly back to the eye
or through transfer to bed sheets or clothes and then back to
the eye. Alternatively, extraocular infection may be a marker of
severe infection that cannot be cleared with a single dose of
azithromycin. Continued efforts to implement the F and E
components of the SAFE strategy (health education to encour-
age face-washing, improvements in water supply to facilitate
face-washing, and measures to control eye-seeking flies) should
be encouraged.
TABLE 4. Adjusted Associations between Nasal Infection at Baseline








Baseline nasal swab positivity
No 1.00 Reference
Yes 5.15 1.54–17.23
Baseline ocular swab positivity
No 1.00 Reference
Yes 6.97 2.0–24.54
TABLE 5. Individuals with Ocular Swab Positivity at 2 Months by
Baseline Nasal and Ocular Swab Status
Baseline Positivity Status
Ocular Positivity at 2 Months
No Yes % Infected
No ocular, no nasal* 89 1 1.1
Ocular only 16 6 27.3
Nasal only 10 4 28.6
Ocular and nasal 26 16 38.1
Total 142 27 16.0
Data are the number and percentage of individuals infected.
* One participant missing ocular positivity status at 2 months.
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